Comparative Pharmacology
Head-to-head clinical analysis: APONVIE versus PROMETHAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APONVIE versus PROMETHAZINE.
APONVIE vs PROMETHAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
APONVIE (pemigatinib) is a selective fibroblast growth factor receptor (FGFR) inhibitor. It binds to and inhibits FGFR1, FGFR2, and FGFR3, thereby suppressing FGFR signaling and reducing proliferation and survival of tumor cells with FGFR alterations.
Promethazine is a phenothiazine derivative that acts as a potent histamine H1 receptor antagonist, thereby blocking the effects of histamine. It also has central anticholinergic, antiemetic, and sedative properties, likely mediated through antagonism at muscarinic, dopamine D2, and serotonin receptors in the brain.
APONVIE is not a recognized drug; no dosing information available.
12.5-25 mg IM or IV every 4-6 hours; also 25 mg PO or PR every 6-8 hours. Maximum 100 mg/day.
None Documented
None Documented
Clinical Note
moderatePromethazine + Risedronic acid
"Promethazine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects."
Clinical Note
moderatePromethazine + Methylphenidate
"Promethazine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects."
Clinical Note
moderatePromethazine + Artesunate
"The serum concentration of Artesunate can be increased when it is combined with Promethazine."
Clinical Note
moderateTerminal elimination half-life is approximately 12 hours in healthy adults; prolonged to 24–36 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life 9-16 hours; may be prolonged in hepatic impairment.
APONVIE is primarily excreted renally as unchanged drug (approx. 70%) and via biliary/fecal routes (approx. 30%).
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal minor.
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic
Promethazine + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Promethazine."